Search

Argenx SE

Open

SectorGezondheidszorg

810.2 0.8

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

797

Max

820.2

Belangrijke statistieken

By Trading Economics

Inkomsten

-315M

506M

Verkoop

-1B

1.7B

K/W

Sectorgemiddelde

31.356

50.373

EPS

7.8

Winstmarge

29.402

Werknemers

1,863

EBITDA

-307M

539M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

-2.07% downside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

830M

49B

Vorige openingsprijs

809.4

Vorige sluitingsprijs

810.2

Argenx SE Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 okt 2026, 23:56 UTC

News
Correlated Moves

Jack Henry & Associates reported $17.9 million in deconversion revenue for Q1 2026 and projected $30 million for fiscal 2027.

29 okt 2026, 23:56 UTC

News

Citigroup maintains Buy rating on Sherwin-Williams, lowering price target to $370; RBC Capital reaffirms Outperform rating, adjusting target to $383.

29 okt 2026, 23:56 UTC

News

Duolingo faces multiple class action lawsuits alleging securities law violations related to false statements on user growth and AI content quality.

29 okt 2026, 23:51 UTC

News

Argus Research downgraded Wendy's Co to Sell, citing concerns over growth prospects and competitive pressures in the fast-food sector.

29 okt 2026, 23:51 UTC

News

Citigroup maintains Neutral rating on Rexford Industrial Realty, lowering its price target to $40 in a report published after market hours.

29 okt 2026, 23:51 UTC

Social Media
News

MGM Resorts' shares declined after Macquarie lowered its price target to $46 and JP Morgan reduced its target to $39 following market close.

29 okt 2026, 23:51 UTC

Macro Event
News

The European Central Bank held interest rates steady at 2.65% in October, aligning with market expectations amid rising inflation concerns.

29 okt 2026, 23:46 UTC

News

JP Morgan maintains Overweight rating on C.H. Robinson Worldwide but lowers price target to $174, contributing to a modest decline in after-market trading.

29 okt 2026, 23:46 UTC

News

Tenable Holdings, Inc. shares advanced in after-market trading as JP Morgan raised its price target to $41 and Canaccord Genuity increased its target to $54.

29 okt 2026, 23:41 UTC

News
Correlated Moves

RBC Capital raised its price target on Prosperity Bancshares to $79, maintaining a Sector Perform rating in a report published after the market closed.

29 okt 2026, 23:41 UTC

News

Olin Corporation reports Q3 net income of $14.4 million and projects Q4 adjusted EBITDA of $80 million to $100 million, citing customer destocking.

29 okt 2026, 23:41 UTC

News

Prospect Capital Corporation prices a $300 million offering of 8.95% unsecured notes due in 2031, aimed at refinancing debt and general corporate purposes.

29 okt 2026, 23:36 UTC

News

The Nikkei 225 Index declined in after-market hours following a drop in Japan's consumer confidence index to 35.0 and Toyota's production cuts in China.

29 okt 2026, 23:31 UTC

News

The euro is gaining against the Norwegian krone as the ECB holds rates steady and warns of rising inflation risks, ending a six-day decline.

29 okt 2026, 23:31 UTC

News

Lennar Corporation filed with the SEC to amend its revolving credit agreement, increasing commitments to $3.80 billion and borrowing capacity to $4.55 billion.

29 okt 2026, 23:26 UTC

News

Macquarie maintains Neutral rating on Hilton Worldwide and raises price target to $333, reflecting a positive assessment of the company's performance and market position.

29 okt 2026, 23:21 UTC

News

JP Morgan maintains Overweight rating on International Paper, lowering price target to $51, reflecting confidence amid a rise in the Paper & Plastic Packaging sector.

29 okt 2026, 23:16 UTC

News

Exelixis reports Q3 2026 revenues of $658.7 million and GAAP net income of $218.1 million, exceeding analyst expectations, while shares declined in after-market trading.

29 okt 2026, 23:16 UTC

News

PG&E Corp shares rose in after-market hours, supported by mixed options sentiment with a put/call ratio of 0.16 and decreased implied volatility at 41.1.

29 okt 2026, 23:16 UTC

News
Correlated Moves

Brown & Brown Inc recognized as a Certified™ Great Place to Work® for the eighth year and included in Fortune's 2026 Best Workplaces lists.

29 okt 2026, 23:12 UTC

News
Correlated Moves

SkyWest, Inc. reported Q3 2026 net income of $119.5 million, or $3.08 per share, with revenue of $1.12 billion, missing analyst expectations.

29 okt 2026, 23:11 UTC

News

New Fortress Energy Inc. leases ten mobile turbines for up to 300 megawatts to a U.S. investment-grade company, enhancing earnings and liquidity.

29 okt 2026, 23:11 UTC

News

Cherry Hill Mortgage Investment Corporation reported Q3 adjusted EPS of $0.14, revenues of $6.558 million, and a net loss of $1.5 million.

29 okt 2026, 23:11 UTC

News

Ethereum is trading lower, reflecting a significant decline since Wednesday's close, amid cautious investor sentiment following the Fed's rate decision and falling crude oil prices.

29 okt 2026, 23:06 UTC

News

Textron Inc reported Q3 revenue of $3.75 billion and raised 2026 GAAP EPS guidance to $5.64-$5.74, with shares advancing in after-market trading.

29 okt 2026, 23:06 UTC

News

JP Morgan maintains Neutral rating on Centene Corp and raises price target to $75 in a report published today.

29 okt 2026, 23:06 UTC

News

Biogen Inc. receives an upgrade to Buy from Argus Research with a price target of $280, while Canaccord Genuity raises its target to $272.

29 okt 2026, 23:06 UTC

News

Ethereum is trading lower, continuing its decline as cautious investor sentiment grows following the Federal Reserve's rate decision and mixed economic signals.

29 okt 2026, 23:06 UTC

News

Bitcoin faces downward pressure amid reports of a potential $2 billion hack linked to Binance, contributing to negative market sentiment and testing local range lows.

29 okt 2026, 23:06 UTC

News

Bitcoin is under downward pressure amid reports of a potential $2 billion hack linked to Binance, testing local range lows as negative sentiment persists.

Peer Vergelijking

Prijswijziging

Argenx SE Prognose

Koersdoel

By TipRanks

-2.07% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 438.33 EUR  -2.07%

Hoogste 545 EUR

Laagste 223 EUR

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Argenx SE - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

5

Buy

0

Hold

1

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
help-icon Live chat